BioSpace News Archive

Cervical spine injuries in children are relatively rare but can have serious consequences, like paralysis.

Sparrow Pharmaceuticals will present interim results from a Phase 2 clinical trial of its novel HSD-1 inhibitor, clofutriben (SPI-62), administered in combination with prednisolone to patients with polymyalgia rheumatica, at the European Congress of Rheumatology (EULAR) 2024 congress in Vienna, Austria during a highlighted session, “The 75th Anniversary of Glucocorticoids - what have we learnt?”

Scilex Holding Company announced that it has the FDA approval of commercial manufacturing of Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. and will launch in June 2024.

QIAGEN announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market development trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems.

Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14th Annual East Coast IDEAS Conference at the Jay Conference Center – Bryant Park in New York City on June 12, 2024.

Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 450,000 shares of the company’s common stock to two new employees on June 3, 2024.

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General and Special Meeting of Shareholders held on June 6, 2024.

Rapport Therapeutics, Inc., a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, announced the pricing of its initial public offering of 8,000,000 shares of its common stock at a public offering price of $17.00 per share.

Geron Corporation announced that the U.S. Food and Drug Administration has approved RYTELO™ for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.

RecoveryOne, a leading virtual musculoskeletal (MSK) care provider dedicated to improving the cost and quality of care, announced its inclusion in an independent evaluation of virtual MSK solutions by Peterson Health Technology Institute (PHTI), a non-profit that evaluates digital health solutions aiming to improve health and lower costs.